Skip to main content
Premium Trial:

Request an Annual Quote

Immunex and Digital Gene Announce Deal To License Molecule

Premium

SEATTLE--Immunex has obtained an experimentation license for a molecule identified by Digital Gene Technology's Total Gene Expression Analysis (TOGA) technology as applied to Immunex's advanced gastrointestinal tract inflammation models in a collaboration begun in December 1997. The molecule will now be studied by Immunex researchers in their ongoing investigation of the molecular basis of gut inflammation pathologies, Immunex stated.

Other molecules from the first-round TOGA results, including both previously known genes new to the inflammation model and a number of never-before-encountered genes, are expected to be added to Immunex's experimentation license this summer.

TOGA is Digital's patented method of identifying and determining the concentration of nearly all of the genes active in a sample cell or tissue. The method, developed at the Scripps Research Institute in the laboratory of Gregor Sutcliffe, a company founder and chairman of Digital's scientific advisory board, provides an inventory of gene activity in a sample and constitutes a major new approach to defining the function of the vast array of genes comprising any genome.

American Home Products owns a majority interest in Immunex.

Filed under

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.